Enhanced anticancer efficacy of

Ítala C Silva, Miguel P de Almeida, Eulália Pereira, Octávio L Franco, Sónia Gonçalves, Nuno C Santos

Abstract read

In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ítala C SilvaGIMM - Gulbenkian Institute for Molecular Medicine, Av. Prof. Egas Moniz, Lisbon, 1649-028, Portugal.

Miguel P de AlmeidaREQUIMTE/LAQV, Departamento de Química e Bioquímica, Faculdade de Ciências da Universidade do Porto, Porto, 4169-007, Portugal.

Eulália PereiraREQUIMTE/LAQV, Departamento de Química e Bioquímica, Faculdade de Ciências da Universidade do Porto, Porto, 4169-007, Portugal.

Octávio L FrancoS-Inova Biotech, Programa de Pós-Graduação em Biotecnologia, Universidade Católica Dom Bosco, Avenida Tamandaré 6000, Campo Grande, MS, Brazil.

Sónia GonçalvesGIMM - Gulbenkian Institute for Molecular Medicine, Av. Prof. Egas Moniz, Lisbon, 1649-028, Portugal.

Nuno C SantosGIMM - Gulbenkian Institute for Molecular Medicine, Av. Prof. Egas Moniz, Lisbon, 1649-028, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer remains a major global health challenge due to its rising incidence and the limitations of conventional chemotherapeutic options. Antimicrobial peptides (AMPs) with dual antimicrobial and anticancer activities have emerged as promising alternatives; however, their clinical application is limited by issues such as stability, selectivity, and delivery. Nanocarrier systems, particularly silver nanostars (AgNSs), can address these challenges by improving peptide delivery and cellular interaction. This study explores the nanocomplex AgNSs-

Indexed as

Anticancer peptideBreast cancerCell membrane interactionsNanomedicineSilver nanostars

Identifiers

PMID42701436

DOI10.1016/j.mtbio.2026.103573

PMCPMC13545356

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.